Quantoom Biosciences

Executive Summary

Quantoom Biosciences is a Belgian biotechnology company founded in 2021 that is reinventing RNA manufacturing technologies to enable faster and more cost-effective development of mRNA- and saRNA-based vaccines and therapeutics. The company positions itself as a full-stack partner, offering end-to-end solutions from sequence design to drug product formulation. By focusing on manufacturing innovation, Quantoom aims to address key bottlenecks in RNA medicine production, such as scalability, cost, and speed, which are critical for expanding access to RNA therapies globally. The company is currently in the pre-clinical stage and is privately held, with no disclosed funding history. Quantoom's approach has the potential to disrupt the RNA manufacturing landscape, particularly for emerging markets and pandemic preparedness, where low-cost, decentralized production is essential.

Upcoming Catalysts (preview)

• Q2 2027Series A Funding Round70% success
• Q4 2026Partnership with a Major Pharma or CMO50% success
• Q1 2027Proof-of-Concept Data for Manufacturing Platform80% success